Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Antoni Torres, Catia Cillóniz, Francesco Blasi, James D. Chalmers, Jacques Gaillat, Nathalie Dartois, Heinz Josef Schmitt, Tobias Welte

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%–78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

Original languageEnglish
Pages (from-to)6-13
Number of pages8
JournalRespiratory Medicine
Volume137
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Pneumonia
Incidence
Streptococcus pneumoniae
Comorbidity
Vaccination
Pneumococcal Vaccines
PubMed

Keywords

  • Community-acquired pneumonia
  • Epidemiology
  • Europe
  • Incidence
  • Pneumococcal
  • Pneumococcal vaccines
  • Pneumonia
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Burden of pneumococcal community-acquired pneumonia in adults across Europe : A literature review. / Torres, Antoni; Cillóniz, Catia; Blasi, Francesco; Chalmers, James D.; Gaillat, Jacques; Dartois, Nathalie; Schmitt, Heinz Josef; Welte, Tobias.

In: Respiratory Medicine, Vol. 137, 01.04.2018, p. 6-13.

Research output: Contribution to journalReview article

Torres, A, Cillóniz, C, Blasi, F, Chalmers, JD, Gaillat, J, Dartois, N, Schmitt, HJ & Welte, T 2018, 'Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review', Respiratory Medicine, vol. 137, pp. 6-13. https://doi.org/10.1016/j.rmed.2018.02.007
Torres, Antoni ; Cillóniz, Catia ; Blasi, Francesco ; Chalmers, James D. ; Gaillat, Jacques ; Dartois, Nathalie ; Schmitt, Heinz Josef ; Welte, Tobias. / Burden of pneumococcal community-acquired pneumonia in adults across Europe : A literature review. In: Respiratory Medicine. 2018 ; Vol. 137. pp. 6-13.
@article{0ac72285654640b69d878bc08e7a8b47,
title = "Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review",
abstract = "Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30{\%}–78{\%}) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.",
keywords = "Community-acquired pneumonia, Epidemiology, Europe, Incidence, Pneumococcal, Pneumococcal vaccines, Pneumonia, Streptococcus pneumoniae",
author = "Antoni Torres and Catia Cill{\'o}niz and Francesco Blasi and Chalmers, {James D.} and Jacques Gaillat and Nathalie Dartois and Schmitt, {Heinz Josef} and Tobias Welte",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.rmed.2018.02.007",
language = "English",
volume = "137",
pages = "6--13",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Burden of pneumococcal community-acquired pneumonia in adults across Europe

T2 - A literature review

AU - Torres, Antoni

AU - Cillóniz, Catia

AU - Blasi, Francesco

AU - Chalmers, James D.

AU - Gaillat, Jacques

AU - Dartois, Nathalie

AU - Schmitt, Heinz Josef

AU - Welte, Tobias

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%–78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

AB - Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%–78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

KW - Community-acquired pneumonia

KW - Epidemiology

KW - Europe

KW - Incidence

KW - Pneumococcal

KW - Pneumococcal vaccines

KW - Pneumonia

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=85042365671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042365671&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2018.02.007

DO - 10.1016/j.rmed.2018.02.007

M3 - Review article

AN - SCOPUS:85042365671

VL - 137

SP - 6

EP - 13

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -